



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Sommadossi, et al.

Confirmation No.:

8101

Serial No.:

10/607,909

Art Unit:

1623

Filed:

June 27, 2003

Examiner:

Travis C. McIntosh III

For:

2'-C-METHYL-3'-O-L-VALINE

Attorney Docket No.: 11874-026-999

ESTER RIBOFURANOSYL

CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS

(417451-999026)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

A copies of References B01 to B23 and C01 to C32 are submitted herewith. References A01 to A97 are U.S. patents and U.S. published applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

Respectfully submitted,

Date:

April 18, 2007

Mark D. Kafka

for:

Reg. No. 59,569 Reg. No. 43,045

04/20/2007 WABDELR1 00000057 10607909

790.00 BA 180.00 DA

C:1801

FC:1806

JONES DAY 222 East 41st Street

Dale L. Rieger

New York, New York 10017

(858) 314-1200

LAI-2865735v1

APR 1 8 2007

ESPECIAL CONTROL OF THE SECOND SECOND

(Use several sheets if necessary)

	Sheet 1 of 0
ATTY. DOCKET NO.	APPLICATION NO.
11874-026-999	10/607,909
APPLICANT	
Sommadossi, et al.	
FILING DATE	ART UNIT
June 27, 2003	1623

*Examiner			Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures
Initials	A01	Document Number 3,116,282	mm/dd/yy 12/31/63	of Cited Document Hunter	Appear
· · · · · · · · · · · · · · · · · · ·	A02	3,891,623	6/24/75	Vorbruggen, et al.	
	A03	3,480,613	11/25/69	Walton, et al.	
£	A04	4,209,613	6/24/80	Vorbruggen, et al.	
	A05	4,294,766	10/13/81	Schmidt, et al.	
-	A06	4,689,404	8/25/87	Kawada, et al.	
	A07	4,754,026	6/28/88	Kawada, et al.	
	A08	4,814,477	3/21/89	Wijnberg, et al.	
	A09	4,952,740	8/28/90	Juge, et al.	
	A10	5,200,514	4/06/93	Chu	
	All	5,322,955	6/21/94	Matsumoto, et al.	
	A12	5,372,808	12/13/94	Blatt, et al.	
	A13	5,391,769	2/21/95	Matsumoto, et al.	
	A14	5,676,942	10/14/97	Testa, et al.	
	A15	5,696,277	12/9/97	Hostetler, at al.	
	A16	5,738,845	4/14/98	Imakawa	
	A17	5,750,676	5/12/98	Vorbruggen, et al.	
	A18	5,763,418	6/9/98	Matsuda, et al.	
	A19	5,780,617	5/31/94	Van Den Bosch, et al.	
	A20	5,789,608	8/4/98	Glazier	
	A21	5,830,455	11/3/98	Valtuena, et al.	-
	A22	5,849,696	12/15/98	Chretien, et al.	
	A23	5,908,621	6/1/99	Glue, et al.	
	A24	5,928,636	7/27/99	Alber, et al.	
	A25	5,942,223	8/24/99	Bazer, et al.	
	A26	5,977,061	11/2/99	De Clerq	
	A27	5,980,884	11/9/99	Blatt, et al.	
	A28	6,002,029	12/14/99	Hostetler, et al.	
	A29	6,063,628	5/16/00	Loeb, et al.	

LAI-2865957v1

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Sommadossi, et al.	
•	FILING DATE	ART UNIT
	June 27, 2003	1623

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where *Examiner Date Name of Patentee or Applicant Relevant Passages or Relevant Figures mm/dd/yy Initials **Document Number** of Cited Document Appear 6,140,310 A30 10/31/00 Glazier 11/28/00 A31 6,153,594 Borretzen, et al. A32 6,172,046 1/09/01 Albrecht A33 6,248,878 6/19/01 Matulic-Adamic, et al. A34 6,252,060 6/26/01 Hostetler, et al. 6,271,212 8/07/01 Chu, et al. A35 6,277,830 8/21/01 Ganguly A36 6,340,690 1/22/02 Bachand, et al. A37 A38 6,369,040 4/09/02 Acevedo, et al. A39 6,395,716 5/28/02 Gosselin, et al. 6,436,437 8/20/02 Yatvin, et al. A40 9/3/02 A41 6,444,652 Gosselin, et al. 6,448,392 9/10/02 Hostetler, et al. A42 A43 6,455,508 9/24/02 Ramasamy, et al. A44 6,472,373 10/29/02 Albrecht 6,566,344 5/20/03 Gosselin, et al. A45 A46 6,566,365 5/20/03 Storer, et al. A47 6,569,837 5/27/03 Gosselin, et al 6,599,887 7/29/03 Hostetler, et al. A48 6,605,614 8/12/03 Bachand, et al. A49 A50 6,748,161 6/8/04 Ko, et al. A51 6,752,981 6/22/04 Erion, et al. A52 6,777,395 8/17/04 Bhat, et al. A53 6,784,161 8/31/04 Ismaili, et al. 9/7/04 A54 6,787,526 Bryant, et al. A55 6,815,542 11/9/04 Hong, et al. 6,831,069 12/14/05 Tam, et al. A56 A57 6,875,751 4/05/05 Imbach, et al. A58 6,908,924 6/21/05 Watanabe, et al.

LAI-2865957v1

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Sommadossi, et al.	
-	FILING DATE	ART UNIT
	June 27, 2003	1623

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where *Examiner Date Name of Patentee or Applicant Relevant Passages or Relevant Figures Initials **Document Number** mm/dd/yy of Cited Document Appear 6,911,424 A59 6/28/05 Schinazi, et al. A60 6,946,450 9/20/05 Gosselin, et al. A61 6,965,066 11/15/05 Jiang, et al. 7,056,895 A62 6/6/06 Ramasamy, et al. 2002/0019363 2/14/02 Ismaili, et al. A63 2002/0052345 5/2/02 Schinazi, et al. A64 2002/0055473 5/09/02 A65 Ganguly, et al. 2002/0055483 5/09/02 Watanabe, et al. A66 2002/0099072 7/25/02 A67 Bachand, et al. A68 2002/0127203 9/12/02 Albrecht A69 2002/0147160 10/10/02 Bhat, et al. 2002/0173490 A70 11/21/02 Jiang, et al. A71 2003/0028013 2/6/03 Wang, et al. 2003/0039630 2/27/03 A72 Albrecht 2003/0050229 3/13/03 A73 Sommadossi, et al. A74 2003/0055013 3/20/03 Brass 3/20/03 A75 2003/0053986 Zahm A76 2003/0083306 5/01/03 Imbach, et al. A77 2003/0083307 5/1/03 Devos, et al. A78 2003/0087873 5/08/03 Stuyver, et al. A79 2004/0110717 6/10/04 Carroll, et al. 2003/0124512 7/03/03 A80 Styuver A81 2003/0225028 12/4/03 Gosselin, et al. 2003/0225037 A82 12/4/03 Storer, et al. 2003/0236216 12/25/03 A83 Devos, et al. 4/1/04 A84 2004/0063622 LaColla, et al. A85 2004/0077587 4/22/04 Sommadossi, et al. A86 2004/0097462 5/20/04 Sommadossi, et al. A87 2004/0102414 5/27/04 Sommadossi, et al.

LAI-2865957v1

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Sommadossi, et al.	
•	FILING DATE	ART UNIT
	June 27, 2003	1623

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figure Appear
	A88	2004/0110718	6/10/04	Devos, et al.	
	A89	2004/0248844	12/9/04	Ismaili, et al.	
•	A90	2004/0266723	12/30/04	Otto, et al.	
	A91	2005/0020825	1/27/05	Storer, et al.	
_	A92	2005/0031588	2/10/05	Sommadossi, et al.	
	A93	2005/0090463	4/28/05	Roberts, et al.	
	A94	2005/0101550	5/12/05	Roberts, et al.	
-	A95	2005/0107312	5/19/05	Keicher, et al.	
	A96	2005/0113330	5/26/05	Imbach, et al.	
	A97	2005/0124532	6/9/05	Sommadossi, et al.	-

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	FR 1,581,628	9/19/69	Merck & Co. Inc.		
	B02	FR 2,662,165	11/22/91	Univ. Pier et Curie		
	B03	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.		
	B04	WO 94/01117	1/20/94	Koszalka, et al.		
	B05	WO 98/16184	4/23/98	ICN Pharmaceuticals		
	B06	WO 00/09531	2/24/00	Novirio Pharmaceuticals		
	B07	WO 01/68663	9/20/01	ICN Pharmaceuticals		
	B08	WO 02/03997	1/17/02	ICN Pharmaceuticals		
	B09	WO 02/070533	9/12/02	Pharmasset		
	B10	WO 02/094289	11/28/02	F. Hoffmann-La Roche		
	B11	WO 02/100415	12/19/02	F. Hoffmann-La Roche		
	B12	WO 03/026589	4/3/03	Idenix Pharma.; CNRS; U. Montp.		
	B13	WO 03/026675	4/3/03	Idenix Pharma.; CNRS; U. Montp.		
	B14	WO 03/063771	8/7/03	Pharmasset		
	B15	WO 03/068162	8/21/03	Pharmasset		_

LAI-2865957v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY. DOCKET NO.	APPLICATION NO.
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Sommadossi, et al.	10/00/1,707
•	FILING DATE	ART UNIT
	June 27, 2003	1623

*Examiner		Foreign Patent Document Country Code, Number,	Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials	D16	Kind Code (if known)	mm/dd/yy	of Cited Document	Figures Appear	
	B16	WO 03/068164	8/21/03	Pharmasset		
	B17	WO 03/072757	9/4/03	Biota Inc.		
•	B18	WO 03/093290	11/13/03	Genelabs Technologies		
	B19	WO 04/002422	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
•	B20	WO 04/002999	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B21	WO 04/003000	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B22	WO 04/028481	4/8/04	Genelabs Technologies		
	B23	WO 04/046159	6/3/04	F. Hoffmann-La Roche		

		NON PATENT LITERATURE DOCUMENTS	
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	C01	Altman, et al., "TheSynthesis of I'-Methyl Carbocyclic Thymidine and Its Effect on Nucleic Acid Duplex Stability," Synlett, Thieme Verlag. Stuttgart, De, 10:853-855 (1994).	
	C02	Beigelman, et al., "Epimerization During the Acetolysis of 3-O-Acetyl-5-O-Benzoyl-1,2-o-Isopropylidene-3-C-Methyl-a, D-Ribofuranose. Synthesis of 3'-C-Methylnucleosides with the B-D-ribo-and a-D-arabino Configurations," Carbohydrate Research, 181:77-88 (1988).	
	C03	Carroll, S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," <i>J. Biol. Chem.</i> , 278(14): 11979-11984 (2003).	
	C04	Faivre-buet, et al., "Synthesis of Various 3'-Branched 2', 3'-Unsaturated Pyrimidine Nucleosides as Potential Anti-HIV Agents," Nucleotides & Nucleosides, 11(7): 1411-1424 (1992).	
	C05	Francesco, et al. Antiviral Research. 58: 1-16 (2003).	
	C06	Grouiller, et al., "Novel-p-toluensesulfaonylation and Thionocarbonylation of Unprotected Thymine Nucleosides," Synlett, 1993: 221-222 (1993).	
	C07	Haraguchi, et al., "Preparation and Reactions of 2'-and 3'- Vinyl Bromides of Uracil Nucleosides: Versatile Synthons for Anti-HIV Agents," Tetrahedron Letters, 32(28): 3391-94 (1991).	
	C08	Haraguchi, et al., "Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides from Uridine," Nucleotides & Nucleosides, 14(3-5): 417-420 (1995).	
	C09	Harry-O'Kuru, R.E., et al., "2'-C-alkylribonucleosides: Design, synthesis, and conformation," <i>Nucleosides & Nucleotides</i> , 16(7-9): 1457-60 (1997).	
	C10	Hattori, H., et al., "Nucleosides and nucleotides 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and – uracil," J. Med. Chem., 41: 2892-2902 (1998).	
	CH	Itoh, et al., "Divergent and Sterocontrolled Approach to the Synthesis of Uracil Nucleosides Branched at the Anomeric Position," J Org Chem, 60(3): 656-662 (1995).	
	C12	Kawana, et al, "The Deoxygenatio of Tosylated Adenosine Derivatives with Grignard Reagents," Nucleic Acids Symp Ser, 17:37-40 (1986).	
	C13	Lavaire, S., et al., "3'-deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," Nucleosides &	

LAI-2865957v1

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Sommadossi, et al.	
•	FILING DATE	ART UNIT
	June 27, 2003	1623

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Nucleotides, 17(12): 2267-2280 (1998).	Т
	C14	Leyssen, P., et al., "Perspectives for the treatment of infections with Flaviviridae," <i>Clinical Microbiology Reviews</i> (Washington D.C.) 13(1): 67-82 (January 2000).	
•	C15	Martin, X., et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-D-piscofuranosyl)nucleoside," <i>Tetrahedron</i> , 50(22): 6689-6694 (1994).	
	C16	Matsuda, A., et al., "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: Synthesis of 2'-branched-sugar pyrimidine nucleosides (Nucleosides and Nucleotides LXXXI)," <i>Chem. Pharm. Bull.</i> , 36(3): 945-953 (1988).	
•	C17	Matasuda, et al., "Nucelosides and Nucleotides 104. Radical and Palladium-Catalyzed Deoxygenation of the Allylic Alcohol Systems in the Sugar Moiety of Pyrimidine Nucelosides" Nucleotides & Nucleosides, 11(2-4): 197-226 (1992)	
	C18	Mikhailov, S.N., et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," <i>Nucleosides & Nucleotides</i> , 10(1-3): 339-343 (1991).	
	C19	Mikhailov, S.N., et al., "Hydrolysis of 2'- and 3'-C-methyluridine 2'c3'-cyclic monophosphates and interconversion and dephosphorlyation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of uridine monophophates," <i>J. Org. Chem.</i> , 57(15): 4122-4126 (1992).	!
	C20	Oivanen, M., et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3', 5'-cyclic monophosphates," <i>J. Chem. Soc. Perkin Trans.</i> 2, 1994: 309-314 (1994).	
	C21	Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A75-77.	
	C22	Samano, et al., "Synthesis and Radical-Induced Ring-Opening Reactions of 2'-Deoxyadenosine-2'-Spirocyclopropane and its Uridine analogue. Mechanistic Probe for Ribonucleotide Reductases," J Am Chem Soc, 114: 4007-08 (1992)	
	C23	Samano, et al., "Nucleic Acid Related Compounds. 7. 2',3'-Didehydro-2', 3'-Dideoxy-2' (and 3')-Methylnucleosides Via [3,3]-Sigmatropic Rearrangements of 2'(and 3')-Methylene-3'(and 2')-O-Thiocarbonyl Derivatives and Radical Reuction of a 2'-Chloro-3'Methylene Analogue," Can. J. Chem., 71: 186-191 (1993)	
	C24	Schmidt, C., et al., "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," <i>Bioorg. & Med. Chem. Lett.</i> , 4(16): 1969-1974 (1994).	
	C25	Serafinowski, P.J., et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," <i>Tetrahedron</i> , 56(2):333-339 (1999).	
_	C26	Tritsch, D., et al., "3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β-branched adenosine substrates of adenosine deaminase," <i>Bioorg. & Med. Chem. Lett.</i> , 10: 139-141 (2000).	
(E. F	C27	Tunitskaya, V.L., et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," <i>FEBS Letters</i> , 400: 263-266 (1997).	
	C28	Vassilev, V., et al., "Bovine Viral Diarrhea Virus Induced Apoptosis Correlates with Increased Intracellular Viral RNA Accumulation." <i>Virus Research</i> , 69: 95-107 (2000).	
	C29	Walczak, K., et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," <i>Acta Chemica Scand.</i> , 45: 930-934 (1991).	
	C30	Walton, E., et al., "Branched-chain sugar nucleosides V. Synthesis and antiviral properties of several branched-chain sugar nucleosides," <i>J. Med. Chem.</i> , 12:306-309 (1969).	
	C31	Wolfe, M.S., et al., "A concise synthesis of 2'-C-methylribonucleosides," <i>Tetrahedron Letters</i> , 36(42): 7611-14 (1995).	
	C32	Wu, et al., "A New Stereospecific Synthesis of [3.1.0\ Bicyclic Cyclopropano Analog of 2'3'-Dideoxyuridine," Tetrahedron, 46(7): 2587-2592 (1990).	

LAI-2865957v1

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.